ImmunoGen Reports Q1 Net Loss, Higher Revenue; Reiterates Full-Year 2021 Outlook
07:00 AM EDT, 05/10/2021 (MT Newswires) -- ImmunoGen (IMGN) reported a Q1 net loss Monday of $0.17 per diluted share, the same as a year ago.
The consensus of analysts polled by Capital IQ expected a loss of $0.19.
Net revenue for the quarter ended March 31 was $15.7 million, up from $13.3 million a year ago.
Analysts polled by Capital IQ expected $17.5 million.
Looking ahead, the company reiterated its fiscal full-year 2021 revenue outlook in the range of $65 million and $75 million.
Price: 7.20, Change: -0.13, Percent Change: -1.77